【2020-ASCO-NSCLC-口服-課件-幻燈】Discussion-Maximizing-benefits-of-EGFR-targeted-therapies_第1頁
【2020-ASCO-NSCLC-口服-課件-幻燈】Discussion-Maximizing-benefits-of-EGFR-targeted-therapies_第2頁
【2020-ASCO-NSCLC-口服-課件-幻燈】Discussion-Maximizing-benefits-of-EGFR-targeted-therapies_第3頁
【2020-ASCO-NSCLC-口服-課件-幻燈】Discussion-Maximizing-benefits-of-EGFR-targeted-therapies_第4頁
【2020-ASCO-NSCLC-口服-課件-幻燈】Discussion-Maximizing-benefits-of-EGFR-targeted-therapies_第5頁
已閱讀5頁，還剩47頁未讀， 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明：本文檔由用戶提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請進(jìn)行舉報或認(rèn)領(lǐng)

文檔簡介

MaximizingtheBenefitsof<br/>(EGFR)TargetedTherapiesPresentedByRachelSanbornatTBDMaximizingtheBenefitsof<brMaximizingtheBenefitsof(EGFR)TargetedTherapiesPresentedByRachelSanbornatTBDMaximizingtheBenefitsof(EGSlide3PresentedByRachelSanbornatTBDSlide3PresentedByRachelSanSlide4PresentedByRachelSanbornatTBDSlide4PresentedByRachelSanSlide5PresentedByRachelSanbornatTBDSlide5PresentedByRachelSanIsTKI/VEGFBetterThanTKIAlone?PresentedByRachelSanbornatTBDIsTKI/VEGFBetterThanTKIAlIsTKI/VEGFBetterThanTKI/Chemo?PresentedByRachelSanbornatTBDIsTKI/VEGFBetterThanTKI/ChSlide8PresentedByRachelSanbornatTBDSlide8PresentedByRachelSanNEJ026,TakeHomePointsPresentedByRachelSanbornatTBDNEJ026,TakeHomePointsPresenOsimertinib+VEGFInhibition?PresentedByRachelSanbornatTBDOsimertinib+VEGFInhibition?PMaximizingtheBenefitsof(EGFR)TargetedTherapiesPresentedByRachelSanbornatTBDMaximizingtheBenefitsof(EGConcurrentosimertinibplusgefitinibforfirst-linetreatmentofEGFR-mutatednon-smallcelllungcancer(NSCLC)PresentedByRachelSanbornatTBDConcurrentosimertinibplusgeFeasibilityPresentedByRachelSanbornatTBDFeasibilityPresentedByRachelRapidplasmaclearanceofEGFRmutationsPresentedByRachelSanbornatTBDRapidplasmaclearanceofEGFROsimertinib+Gefitinib,ConsiderationsPresentedByRachelSanbornatTBDOsimertinib+Gefitinib,ConsiOsimertinib+Gefitinib,TakeHomePointsPresentedByRachelSanbornatTBDOsimertinib+Gefitinib,TakeMaximizingtheBenefitsof(EGFR)TargetedTherapiesPresentedByRachelSanbornatTBDMaximizingtheBenefitsof(EGFirst-LineTyrosineKinaseInhibitorWithorWithoutAggressiveUpfrontLocalRadiationTherapyInPatientsWithEGFRmOligometastaticNon-Small-CellLungCancer:InterimResultsofARandomizedPhaseIII,Open-LabelClinicalTrial(SINDAS)(NCT02893332).PresentedByRachelSanbornatTBDFirst-LineTyrosineKinaseInhSINDAS:Participants’CharacteristicsPresentedByRachelSanbornatTBDSINDAS:Participants’CharactKaplan-MeierplotofPFS(A)andOS(B)PresentedByRachelSanbornatTBDKaplan-MeierplotofPFS(A)aToxicity（Grade3adverseevents）PresentedByRachelSanbornatTBDToxicity（Grade3adverseeventSlide22PresentedByRachelSanbornatTBDSlide22PresentedByRachelSaSINDASTrial,QuestionsandTakeHomePointsPresentedByRachelSanbornatTBDSINDASTrial,QuestionsandTaSINDASTrial,TakeHomePoints,2PresentedByRachelSanbornatTBDSINDASTrial,TakeHomePointsMaximizingtheBenefitsof(EGFR)TargetedTherapiesPresentedByRachelSanbornatTBDMaximizingtheBenefitsof(EGThankyou!PresentedByRachelSanbornatTBDThankyou!PresentedByRachelMaximizingtheBenefitsof<br/>(EGFR)TargetedTherapiesPresentedByRachelSanbornatTBDMaximizingtheBenefitsof<brMaximizingtheBenefitsof(EGFR)TargetedTherapiesPresentedByRachelSanbornatTBDMaximizingtheBenefitsof(EGSlide3PresentedByRachelSanbornatTBDSlide3PresentedByRachelSanSlide4PresentedByRachelSanbornatTBDSlide4PresentedByRachelSanSlide5PresentedByRachelSanbornatTBDSlide5PresentedByRachelSanIsTKI/VEGFBetterThanTKIAlone?PresentedByRachelSanbornatTBDIsTKI/VEGFBetterThanTKIAlIsTKI/VEGFBetterThanTKI/Chemo?PresentedByRachelSanbornatTBDIsTKI/VEGFBetterThanTKI/ChSlide8PresentedByRachelSanbornatTBDSlide8PresentedByRachelSanNEJ026,TakeHomePointsPresentedByRachelSanbornatTBDNEJ026,TakeHomePointsPresenOsimertinib+VEGFInhibition?PresentedByRachelSanbornatTBDOsimertinib+VEGFInhibition?PMaximizingtheBenefitsof(EGFR)TargetedTherapiesPresentedByRachelSanbornatTBDMaximizingtheBenefitsof(EGConcurrentosimertinibplusgefitinibforfirst-linetreatmentofEGFR-mutatednon-smallcelllungcancer(NSCLC)PresentedByRachelSanbornatTBDConcurrentosimertinibplusgeFeasibilityPresentedByRachelSanbornatTBDFeasibilityPresentedByRachelRapidplasmaclearanceofEGFRmutationsPresentedByRachelSanbornatTBDRapidplasmaclearanceofEGFROsimertinib+Gefitinib,ConsiderationsPresentedByRachelSanbornatTBDOsimertinib+Gefitinib,ConsiOsimertinib+Gefitinib,TakeHomePointsPresentedByRachelSanbornatTBDOsimertinib+Gefitinib,TakeMaximizingtheBenefitsof(EGFR)TargetedTherapiesPresentedByRachelSanbornatTBDMaximizingtheBenefitsof(EGFirst-LineTyrosineKinaseInhibitorWithorWithoutAggressiveUpfrontLocalRadiationTherapyInPatientsWithEGFRmOligometastaticNon-Small-CellLungCancer:InterimResultsofARandomizedPhaseIII,Open-LabelClinicalTrial(SINDAS)(NCT02893332).PresentedByRachelSanbornatTBDFirst-LineTyrosineKinaseInhSINDAS:Participants’CharacteristicsPresentedByRachelSanbornatTBDSINDAS:Participants’CharactKaplan-MeierplotofPFS(A)andOS(B)PresentedByRachelSanbornatTBDKaplan-MeierplotofPFS(A)aToxicity（Grade3adverseevents）PresentedByRachelSanbornatTBDToxicity（Grade3adverseeventSlide22PresentedByRachelSanbornatTBDSlide22PresentedByRachelSaSINDASTrial,QuestionsandTakeHomePointsPresentedByRachelSanbornatTBDSINDASTrial,QuestionsandTaSINDASTri

溫馨提示

  • 1. 本站所有資源如無特殊說明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽，若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間，僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請與我們聯(lián)系，我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論